TScan Therapeutics Inc
TCRX
View Detailed Chart
1.030USD
+0.120+13.14%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
58.45MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+13.14%
5 Days
+0.98%
1 Month
-9.65%
6 Months
-40.46%
Year to Date
+3.00%
1 Year
-56.54%
View Detailed Chart
TradingKey Stock Score of TScan Therapeutics Inc
Currency: USD Updated: 2026-02-06Key Insights
TScan Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 109 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.00.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
TScan Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
TScan Therapeutics Inc Highlights
StrengthsRisks
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.82M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.82M.
Overvalued
The company’s latest PE is -0.92, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 39.04M shares, decreasing 22.03% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 829.92K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.36.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
7.000
Target Price
+668.89%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
TScan Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
TScan Therapeutics Inc Info
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
Ticker SymbolTCRX
CompanyTScan Therapeutics Inc
CEOMacbeath (Gavin)
Websitehttps://www.tscan.com
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69206.620
-763.510 (-1.09%)
282.580
+22.390 (+8.61%)
2064.850
+13.120 (+0.64%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
